2022
Optimization of the BCLC Staging System for Locoregional Therapy for Hepatocellular Carcinoma by Using Quantitative Tumor Burden Imaging Biomarkers at MRI.
Borde T, Nezami N, Laage Gaupp F, Savic LJ, Taddei T, Jaffe A, Strazzabosco M, Lin M, Duran R, Georgiades C, Hong K, Chapiro J. Optimization of the BCLC Staging System for Locoregional Therapy for Hepatocellular Carcinoma by Using Quantitative Tumor Burden Imaging Biomarkers at MRI. Radiology 2022, 304: 228-237. PMID: 35412368, PMCID: PMC9270683, DOI: 10.1148/radiol.212426.Peer-Reviewed Original ResearchConceptsMedian overall survivalAdvanced-stage hepatocellular carcinomaTransarterial chemoembolizationHepatocellular carcinomaBCLC BBCLC COverall survivalTumor burdenBarcelona Clinic Liver Cancer (BCLC) staging systemLiver Cancer staging systemCancer (AJCC) staging systemConventional transarterial chemoembolizationDrug-eluting beadsAllocation of patientsContrast-enhanced MRIBackground PatientsSurvival benefitRetrospective studyStaging systemC tumorsTumor volumePatientsHeterogeneous patientsMonthsChemoembolizationImpact of Chemoembolic Regimen on Immune Cell Recruitment and Immune Checkpoint Marker Expression following Transcatheter Arterial Chemoembolization in a VX2 Rabbit Liver Tumor Model
Berz AM, Santana JG, Iseke S, Gross M, Pekurovsky V, Laage Gaupp F, Savic LJ, Borde T, Gottwald LA, Boustani AM, Gebauer B, Lin M, Zhang X, Schlachter T, Madoff DC, Chapiro J. Impact of Chemoembolic Regimen on Immune Cell Recruitment and Immune Checkpoint Marker Expression following Transcatheter Arterial Chemoembolization in a VX2 Rabbit Liver Tumor Model. Journal Of Vascular And Interventional Radiology 2022, 33: 764-774.e4. PMID: 35346859, PMCID: PMC9344951, DOI: 10.1016/j.jvir.2022.03.026.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibiotics, AntineoplasticBicarbonatesCarcinoma, HepatocellularChemoembolization, TherapeuticDoxorubicinLiver NeoplasmsProgrammed Cell Death 1 ReceptorRabbitsConceptsTranscatheter arterial chemoembolizationCytotoxic T-lymphocyte-associated protein 4Rabbit liver tumor modelConventional TACEImmune checkpoint marker expressionLiver tumor modelVX2 rabbit liver tumor modelArterial chemoembolizationBicarbonate infusionImmune responseDifferentiation 3T-lymphocyte-associated protein 4Conventional transcatheter arterial chemoembolizationTumor modelCell death protein 1Marker expressionIntratumoral T cellsImmune checkpoint markersT cell infiltrationDeath protein 1Antigen-presenting cellsImmune cell recruitmentNew Zealand white rabbitsZealand white rabbitsAPC infiltration
2021
Identifying enhancement-based staging markers on baseline MRI in patients with colorectal cancer liver metastases undergoing intra-arterial tumor therapy
Ghani MA, Fereydooni A, Chen E, Letzen B, Laage-Gaupp F, Nezami N, Deng Y, Gan G, Thakur V, Lin M, Papademetris X, Schernthaner RE, Huber S, Chapiro J, Hong K, Georgiades C. Identifying enhancement-based staging markers on baseline MRI in patients with colorectal cancer liver metastases undergoing intra-arterial tumor therapy. European Radiology 2021, 31: 8858-8867. PMID: 34061209, PMCID: PMC8848338, DOI: 10.1007/s00330-021-08058-7.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkersCarcinoma, HepatocellularChemoembolization, TherapeuticColorectal NeoplasmsHumansLiver NeoplasmsMagnetic Resonance ImagingRetrospective StudiesTumor BurdenConceptsColorectal cancer liver metastasesCancer liver metastasesTotal tumor volumeIntra-arterial therapyTotal liver volumeLiver metastasesTumor volumeTumor burdenTumor diameterPatient survivalBaseline MRILiver volumeMultivariable Cox proportional hazards modelsKaplan-Meier survival curvesWhole liverCox proportional hazards modelKaplan-Meier methodPrognostic staging systemSurvival of patientsColorectal cancer metastasisMethodsThis retrospective studyPre-treatment MRIProportional hazards modelAppropriate cutoff valueHR 1.7Lipiodol as an intra-procedural imaging biomarker for liver tumor response to transarterial chemoembolization: Post-hoc analysis of a prospective clinical trial
Letzen BS, Malpani R, Miszczuk M, de Ruiter QMB, Petty CW, Rexha I, Nezami N, Laage-Gaupp F, Lin M, Schlachter TR, Chapiro J. Lipiodol as an intra-procedural imaging biomarker for liver tumor response to transarterial chemoembolization: Post-hoc analysis of a prospective clinical trial. Clinical Imaging 2021, 78: 194-200. PMID: 34022765, PMCID: PMC8364875, DOI: 10.1016/j.clinimag.2021.05.007.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkersCarcinoma, HepatocellularChemoembolization, TherapeuticEthiodized OilHumansLiver NeoplasmsProspective StudiesRetrospective StudiesTreatment OutcomeConceptsConventional trans-arterial chemoembolizationMedian overall survivalProspective clinical trialsLipiodol depositionTumor responsePredictive biomarkersClinical trialsModified Response Evaluation CriteriaPost-TACE CTResponse Evaluation CriteriaMetastatic liver cancerKaplan-Meier analysisTrans-arterial chemoembolizationTumor response criteriaLiver tumor responsePrediction of survivalSelective drug targetingArterial embolizationLiver metastasesOverall survivalBland-Altman plotsTransarterial chemoembolizationPortal veinTumor respondersHepatocellular carcinoma
2020
Reliable prediction of survival in advanced-stage hepatocellular carcinoma treated with sorafenib: comparing 1D and 3D quantitative tumor response criteria on MRI
Doemel LA, Chapiro J, Laage Gaupp F, Savic LJ, Kucukkaya AS, Petukhova A, Tefera J, Zeevi T, Lin M, Schlachter T, Jaffe A, Strazzabosco M, Patel T, Stein SM. Reliable prediction of survival in advanced-stage hepatocellular carcinoma treated with sorafenib: comparing 1D and 3D quantitative tumor response criteria on MRI. European Radiology 2020, 31: 2737-2746. PMID: 33123796, PMCID: PMC8043967, DOI: 10.1007/s00330-020-07381-9.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsCarcinoma, HepatocellularHumansLiver NeoplasmsMagnetic Resonance ImagingPhenylurea CompoundsRetrospective StudiesSorafenibTreatment OutcomeConceptsTumor response criteriaOverall survivalAdvanced-stage HCCDisease progressionSorafenib therapyDisease controlResponse criteriaCox proportional hazards regression modelAdvanced-stage hepatocellular carcinomaProportional hazards regression modelsDCE-MRIInitiation of sorafenibTumor response analysisMultivariable Cox regressionIndependent risk factorMethodsThis retrospective analysisIndependent prognostic factorInitiation of treatmentKaplan-Meier analysisKaplan-Meier curvesHazards regression modelsLog-rank testStratification of patientsTotal tumor volumeArterial phase MRINeutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of tumor response in hepatocellular carcinoma after DEB-TACE
Schobert IT, Savic LJ, Chapiro J, Bousabarah K, Chen E, Laage-Gaupp F, Tefera J, Nezami N, Lin M, Pollak J, Schlachter T. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of tumor response in hepatocellular carcinoma after DEB-TACE. European Radiology 2020, 30: 5663-5673. PMID: 32424595, PMCID: PMC7483919, DOI: 10.1007/s00330-020-06931-5.Peer-Reviewed Original ResearchMeSH KeywordsAgedBlood PlateletsCarcinoma, HepatocellularChemoembolization, TherapeuticFemaleHumansInflammationKaplan-Meier EstimateLiver NeoplasmsLymphocytesMagnetic Resonance ImagingMaleMiddle AgedMultivariate AnalysisNeutrophilsPrognosisProgression-Free SurvivalProportional Hazards ModelsRetrospective StudiesTreatment OutcomeConceptsProgression-free survivalTreatment-naïve hepatocellular carcinomaShorter progression-free survivalPoor tumor responseDEB-TACELymphocyte ratioTumor responseHepatocellular carcinomaMagnetic resonance imagingTumor growthInflammatory biomarkersDrug-eluting bead transarterial chemoembolizationContrast-enhanced magnetic resonance imagingHigher baseline NLRHigher baseline plateletsRadiomic featuresVolumetric tumor responseLoco-regional therapyAlpha-fetoprotein levelsBead transarterial chemoembolizationKaplan-Meier analysisMethodsThis retrospective studyDifferential blood countQuantitative European AssociationNodular tumor growth
2018
Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma.
Abajian A, Murali N, Savic LJ, Laage-Gaupp FM, Nezami N, Duncan JS, Schlachter T, Lin M, Geschwind JF, Chapiro J. Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma. Journal Of Visualized Experiments 2018 PMID: 30371657, PMCID: PMC6235502, DOI: 10.3791/58382.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, HepatocellularHumansInjections, Intra-ArterialLiver NeoplasmsMachine LearningMaleMiddle AgedSurgery, Computer-AssistedConceptsIntra-arterial therapyN patientsHepatocellular carcinomaTrans-arterial therapiesIntra-arterial treatmentCohort of patientsStandard of careLikelihood of responseClinical research questionsSurgical resectionNew patientsTreatment responseUnivariate associationsPatientsTraining patientsInterventional radiologyTherapyCarcinomaTreatmentImage-guided therapyOutcomesFinal modelImaging dataResectionResponsePredicting Treatment Response to Intra-arterial Therapies for Hepatocellular Carcinoma with the Use of Supervised Machine Learning—An Artificial Intelligence Concept
Abajian A, Murali N, Savic LJ, Laage-Gaupp FM, Nezami N, Duncan JS, Schlachter T, Lin M, Geschwind JF, Chapiro J. Predicting Treatment Response to Intra-arterial Therapies for Hepatocellular Carcinoma with the Use of Supervised Machine Learning—An Artificial Intelligence Concept. Journal Of Vascular And Interventional Radiology 2018, 29: 850-857.e1. PMID: 29548875, PMCID: PMC5970021, DOI: 10.1016/j.jvir.2018.01.769.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic AgentsCarcinoma, HepatocellularChemoembolization, TherapeuticContrast MediaDoxorubicinEthiodized OilFemaleHumansLiver NeoplasmsMachine LearningMagnetic Resonance ImagingMaleMiddle AgedNeoplasm StagingPredictive Value of TestsRetrospective StudiesSensitivity and SpecificityTreatment OutcomeConceptsTransarterial chemoembolizationHepatocellular carcinomaTreatment responseLogistic regressionClinical patient dataPatient dataIntra-arterial therapyQuantitative European AssociationMagnetic resonance imagingLiver criteriaBaseline imagingClinical variablesTumor responseTherapeutic featuresTreatment respondersBaseline MRClinical informationImaging variablesChemoembolizationTherapeutic outcomesResonance imagingResponse criteriaEuropean AssociationPatientsMR imaging